Sanofi loses preemption argument ahead of cancer drug Taxotere bellwether trial
New Delhi: Federal law does not shield Sanofi from a woman's claim that it failed to warn her that its cancer drug Taxotere could cause permanent hair loss, a federal court has ruled, a victory for the plaintiff in the second bellwether trial scheduled in a multidistrict litigation over the drug.
Read also: Sanofi wins EU approval for Dupixent for atopic dermatitis in children
U.S. District Judge Jane Triche Milazzo in New Orleans on Friday rejected Sanofi's argument that it could not have revised its FDA-approved label, which did not warn of permanent hair loss, at the time of plaintiff Elizabeth Kahn's Taxotere treatment in 2008.
Read also: Sanofi, GSK delay Covid vaccine program to improve immune response
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.